Evercore analyst Vijay Kumar maintains $GE HealthCare Technologies (GEHC.US)$ with a buy rating, and adjusts the target price from $96 to $102.
According to TipRanks data, the analyst has a success rate of 57.6% and a total average return of 5.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $GE HealthCare Technologies (GEHC.US)$'s main analysts recently are as follows:
In the MedTech sector, continued positive utilization trends are observed going into Q3, and the capital expenditure forecast for the coming year appears favorable. For life science tools, there is an anticipation of improved bioprocess trends in the latter half of the year. Nevertheless, discussions persist regarding the prospects for instruments and the potential impact of China's economic stimulation, especially considering the recent performance of stocks in this segment.
GE Healthcare was the recipient of favorable news when the FDA granted approval for Flurpiridaz, a novel myocardial perfusion imaging (MPI) positron emission tomography (PET) radiopharmaceutical. This product stands out as it is available as a pre-made 'individual dose,' a significant advantage over current on-site dose production methods. According to due diligence with physicians, there is a consensus that Flurpiridaz may offer notable clinical benefits over existing MPI radiopharmaceuticals. Additionally, a swift adoption by current U.S. cardiac PET centers is anticipated, and the availability of Flurpiridaz is expected to substantially widen the scope of U.S. cardiac PET procedures.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
